2-亚氨基硫杂环戊烷 | 6539-14-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 亚氨硫酯类
• 中文名称: 2-亚氨基硫杂环戊烷
• 英文名称: 2-imino-thiolane
• 英文别名: tetrahydrothiophene-2-imine；2-iminothiolane；Traut's reagent；iminothiolane；dihydro-thiophen-2-ylideneamine；2-iminothiolane on aequorin；thiolan-2-imine
• CAS: 6539-14-6
• 化学式: C₄H₇NS
• mdl: MFCD00216010
• 分子量: 101.172
• InChiKey: CNHYKKNIIGEXAY-UHFFFAOYSA-N

物化性质

• 沸点：
  142.6±23.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  49.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-亚氨基硫杂环戊烷 、 chitosan trimer 以 aq. phosphate buffer 为溶剂， 生成
  参考文献：
  名称：

  一种以壳三糖为内置佐剂的合成 Tn-BSA 结合疫苗

  摘要：

  壳三糖（CTS）是壳聚糖的水解产物，由于低聚物的链长较短且d中含有游离氨基，因此很容易溶于水。-葡萄糖胺单位。在本研究中，我们报道了以壳三糖为内置佐剂的新型结合疫苗Tn-BSA-CTS的合成，并评估了佐剂壳三糖（CTS）的效果。对所得结合疫苗的免疫学评估表明，Tn-BSA-CTS 可以激发最高滴度的 IgG 抗体 (102,400)。Tn-BSA-CTS 缀合物显着增强体液免疫和细胞免疫。所获得的结果证明了CTS作为一种新型疫苗佐剂在抗肿瘤疫苗开发中的潜力，并且肿瘤疫苗与CTS的共价连接可能是提高抗癌功效的可用策略。

  DOI：

  10.1016/j.carres.2023.108875
• 作为产物：
  描述：

  2-azidotetrahydrothiophene 在 溴苯 作用下， 以 甲苯 为溶剂， 反应 20.0h， 以62%的产率得到2-亚氨基硫杂环戊烷
  参考文献：
  名称：

  Still, Ian W. J.; Brown, William L.; Colville, Robin J., Canadian Journal of Chemistry, 1984, vol. 62, p. 586 - 590

  摘要：

  DOI：

文献信息

• Preparation of fluorescence-labeled and cross-linked subtilisin.
  作者：Kazutaka TANIZAWA、Tsutomu MANO、Yuichi KANAOKA

  DOI：10.1248/cpb.38.464

  日期：——

  Streptomyces subtilisin inhibitor (SSI) is a protein characterized by both its potent inhibitory activity toward subtilisin and its structure, composed of two homologous subunits. It binds two molecules of subtilisin to form a tetrameric complex.Intermolecularly cross-linked subtilisin is expected to form a polymeric complex with SSI. This could provide a useful model of protein-protein associatin. Therefore, Preparation of fluorescence-labeled and cross-linked subtilisin was carried out.

  链霉菌亚硫蛋白酶抑制剂（SSI）是一种蛋白质，具有对亚硫蛋白酶的强抑制活性，并且其结构由两个同源亚基组成。它能结合两个亚硫蛋白酶分子形成四聚体复合物。通过分子间交联的亚硫蛋白酶预计将与SSI形成聚合复合物。这可以提供一个有用的蛋白质-蛋白质结合模型。因此，进行了荧光标记和交联亚硫蛋白酶的制备。
• Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs
  申请人：Ghoshal Mitali

  公开号：US20050153439A1

  公开（公告）日：2005-07-14

  The present invention comprises novel analogs of ecstasy-class compounds and novel ecstasy-class immunogens leashed out of, i.e., derived from, the methylenedioxy position. The invention also comprises unique monoclonal antibodies generated using MDO-leashed MDMA immunogens as well as unique conjugates and tracers. These antibodies, conjugates, and tracers are useful in immunoassays for the detection of ecstasy-class compounds in biological fluids.

  本发明涉及新型的仿MDMA类化合物和从亚甲二氧基位置衍生出来的新型MDMA类免疫原。该发明还包括使用MDO-leashed MDMA免疫原生成的独特单克隆抗体，以及独特的结合物和示踪剂。这些抗体，结合物和示踪剂在生物体液中检测MDMA类化合物的免疫测定中有用。
• Fusogenic lipids and vesicles
  申请人：Isis Pharmaceuticals, Inc.

  公开号：US20030082154A1

  公开（公告）日：2003-05-01

  Novel lipid compounds are provided that may be termed “pro-cationic” in that they are neutral or negatively charged until they are either brought into contact with cellular membranes or are internalized by cells. The lipids have a hydrophobic tail group and a hydrophilic head group, the head group incorporating both a positively and negatively charged region at physiological pH. The hydrophobic tail group is stably connected to the positive region of the head group which in turn is connected to the negative region by a disulfide bond that is susceptible to cleavage by membrane-bound and intracellular factors. Cleavage of the disulfide bond removes the negatively charged region from the head group resulting in a lipid that is cationic and therefor fusogenic with negatively charged cell membranes. Consequently, lipids of the invention are useful as components of liposomes that serve as vehicles for delivering pharmaceutical agents into cells with reduced toxicity.

  本发明提供了一种称为“前阳离子”的新型脂质化合物，其在与细胞膜接触或被细胞内摄取之前是中性或带负电荷的。该脂质化合物具有疏水尾基和亲水头基，头基在生理pH下包含正电荷和负电荷区域。疏水尾基稳定地连接到头基的正电荷区域，而正电荷区域则通过可被膜结合和细胞内因素裂解的二硫键连接到负电荷区域。断裂二硫键会去除头基的负电荷区域，从而产生带正电荷的脂质化合物，与带负电荷的细胞膜融合。因此，本发明的脂质化合物可用作脂质体的组成部分，用于将药物传递到细胞内，同时减少毒性。
• Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
  申请人：Diamond L. Scott

  公开号：US20050069577A1

  公开（公告）日：2005-03-31

  The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid or cationic drug molecules for use as delivery vehicles. The invention further relates to methods for using cationic steroid molecules in lipofection or transfection, delivery of drugs, and for treatment of inflammation and other diseases and disorders. The invention also relates to cationic steroid prodrugs and cationic prodrugs and to methods of modifying drugs.

  本发明涉及一种用于制备阳离子类固醇或阳离子类药物分子的一步合成技术的组合物和方法，用作传递载体。该发明还涉及使用阳离子类固醇分子进行脂质体转染或转染、药物传递以及治疗炎症和其他疾病和障碍的方法。该发明还涉及阳离子类固醇前药和阳离子前药以及修改药物的方法。
• Synthesis and Use of Cationic Steroids for Anti-Inflammatory Drug Therapy
  申请人：Diamond Scott L.

  公开号：US20090124591A1

  公开（公告）日：2009-05-14

  The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid pharmaceutical compositions for use in treating inflammation and other diseases and disorders.

  本发明涉及一种用于制备阳离子类固醇药物组合物的一步合成技术及其用于治疗炎症和其他疾病和障碍的方法。